Selected Publications

Ortega-Legaspi JM, Molina M, Leon J, Cunningham A, Guerraty M, Peyster E, Julien H, McLean R, Goldberg L, Bravo PE. : Coronary Flow Reserve is an Independent Predictor of Major Adverse Cardiovascular Events in Long Term Heart Transplantation Survivors. The Journal of Heart and Lung Transplantation. ISHLT annual meeting.Denver, CO, USA. April 2023. 2023.

20. Chirinos JA, Lopez-Jaramillo P, Giamarellos-Bourboulis EJ, Dávila-Del-Carpio GH, Bizri AR, Andrade-Villanueva JF, Salman O, Cure-Cure C, Rosado-Santander NR, Cornejo Giraldo MP, González-Hernández LA, Moghnieh R, Angeliki R, Cruz Saldarriaga ME, Pariona M, Medina C, Dimitroulis I, Vlachopoulos C, Gutierrez C, Rodriguez-Mori JE, Gomez-Laiton E, Cotrina Pereyra R, Ravelo Hernández JL, Arbañil H, Accini-Mendoza J, Pérez-Mayorga M, Milionis C, Poulakou G, Sánchez G, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-García RJ, Castro-Callirgos CA, Alfaro Carrasco RM, Garrido Lecca Danos W, Sharkoski T, Greene K, Pourmussa B, Greczylo C, Ortega-Legaspi J, Jacoby D, Chittams J, Katsaounou P, Alexiou Z, Sympardi S, Sweitzer NK, Putt M, Cohen JB; FERMIN Investigators.: A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019. Nat Metab. 2022 Dec;4(12):1847-1857. doi: 10.1038/s42255-022-00698-3. Epub 2022 Nov 7. PMID: 36344766; PMCID: PMC9640855. 4(12): 1847, December 2022.

19. Ali A, Ortega-Legaspi JM: Is it time to adopt angiotensin receptor-neprilysin inhibitors (ARNI) therapy as standard of care for the management of hypertension? Ann Palliat Med. 2022 Oct;11(10):3040-3042. doi: 10.21037/apm-22-1073. PMID: 36367003. 11(10): 3040, October 2022.

McCaffrey JA, Dhakal BP, Nathan AS, Ortega-Legaspi J, Fiorilli PN, Mather PJ, Supple GE. : Loss of Right Atrial Pacing Lead Capture Due to Myocardial Infarction Obscuring Diagnosis on Electrocardiogram. JACC Case Rep. 2022 Jul 20;4(14):890-894. doi: 10.1016/j.jaccas.2022.06.001. eCollection 2022 Jul 20. 20(4): 890, July 2022.

17. Pellicer F, Ortega-Legaspi JM, Martín R, Solís-Nájera S, Magis-Weinberg L, León-Olea M, Graff-Guerrero A, de la Fuente-Sandoval C, Rodriguez AO. : Tracking the Temporal Footprint Effect of Thermonociception and Denervation on the Brain's Pain Matrix: fMRI and BOLD Study in Rats. J Pain Res. 2022 Mar 30;15:857-865. doi: 10.2147/JPR.S349840. eCollection 2022. 30(15): 857, March 2022.

Ortega-Legaspi JM, Bravo PE: Diagnosis and management of cardiac allograft vasculopathy. Heart Aug 2021.

A. Morris, M. Flattery, J. Ortega-Legaspi, A. Devore, T. Alexy, P. Shah, K. Nair, R. T. Cole: The Risk of Leukopenia with Universal vs. Preemptive Prophylaxis Strategies in Heart Transplant Recipients at Intermediate Risk for CMV Complications. Journal of Heart and Lung Transplantation 2021 Notes: Oral presentation.

T. Alexy, A. Morris, M. Flattery, J. Ortega-Legaspi, A. Devore, P. Shah6 S. Sinha, R. T. Cole: Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R+) for Post-Transplant CMV Complications. Journal of Heart and Lung Transplantation 2021 Notes: Oral presentation.

R. T. Cole, A. Devore, A. Morris, T. Alexy, J. M. Ortega-Legaspi, M. Flattery, E. Maziarz, M. Molina, E. Udeshi, K. Shah, C. Martin, V. Maharaj, P. Shah.: A Multi-Center Study of CMV Prophylaxis Strategies in Intermediate Risk (R+) Heart Transplant Recipients. Journal of Heart and Lung Transplantation. 2021 Notes: Oral presentation.

J. Ortega-Legaspi, A. Morris, M. Flattery, T. Alexy, A. Devore, V. Maharaj, C. Martin, E. Maziarz, L. Cooper, K. Shah, M. Molina, E. Udeshi, P. Shah7, R. T. Cole: Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R+) for CMV Complications. Journal of Heart and Lung Transplantation 2021 Notes: Oral presentation.